Sun Pharmaceutical Industries has declared that it will discontinue selling generic version of Sanofi-Aventis cancer drug Eloxatin in the US market by the coming month (July 2010).

The Mumbai-based company took this decision following an order by a New Jersey court.

The company had appealed the court order and plans to litigate the matter before the United States Court of Appeals for the Federal Circuit.

Sun Pharma asserted that the grounds for petition are strong and plans to contest the entry of the Consent Judgment and Order vigorously.

After hearing a positive judgment from the appellate court, Sun has decided to re-start the sales of the product.

In March this year, a division of Sun Pharmaceutical, Caraco Pharmaceutical Labs, stated that during the month of March, it had introduced the generic version of anti-cancer drug oxaliplatin in the form of jab in the US market.

In April this year, Sanofi-Aventis cleared up a patent charge over Eloxatin with other drug manufacturers, blocking them from selling their generic edition in the United States from June 30 until August 2012.